Literature DB >> 12764696

Increased cycle length variability during ventricular fibrillation: a novel predictor of arrhythmia recurrence.

Hisashi Yokoshiki1, Tetsuro Kohya, Minoru Sato, Koji Sasaki, Akihiko Yotsukura, Masayuki Sakurai, Akira Kitabatake.   

Abstract

To evaluate the clinical value of cycle length (CL) variability during ventricular fibrillation (VF), 26 patients who underwent implantable cardioverter defibrillator (ICD) implantation were enrolled. In VF induced for defibrillation testing, mean and SD of VFCL, mean successive differences (MSD) of VFCL, and coefficient of variations of the VFCL (CV(FF)) (SD x 100/mean VFCL) were calculated. During the follow-up period of 20 +/- 2 months, ventricular arrhythmias recurred in 13 patients. MSD and CV(FF) were 31 +/- 3(*) ms and 15.6 +/- 1.3(**) in recurrence group (n = 13), and 17 +/- 2 ms and 9.0 +/-1.1 in non-recurrence group (n = 13) ((*)P <.005, (**)P <.001 vs. nonrecurrence group). Relatively good repeatability of mean VFCL, MSD and CV(FF) in each patient was confirmed by the Bland-Altman method. In VF induced by programmed ventricular stimulation before ICD implantation, MSD and CV(FF) in recurrence group were also increased significantly. Kaplan-Meier estimates revealed that MSD >or= 20 ms and CV(FF) >or= 12 predicted higher arrhythmia recurrence (MSD, P =.039; CV(FF), P =.0069 by the log-rank test). By multivariate analysis, CV(FF) >or= 12 was a significant predictor of recurrent arrhythmic events (P =.019). In conclusion, the CL variability of VF, which was evaluated as MSD and CV(FF), is increased in patients with arrhythmia recurrence. These values may reflect the degree of electrical heterogeneity, and appears to be useful indexes of the future arrhythmic events.

Entities:  

Mesh:

Year:  2003        PMID: 12764696     DOI: 10.1054/jelc.2003.50018

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  2 in total

1.  The impact of catecholamines in patients with or without beta-blockers on the ventricular fibrillation cycle length and ventricular fibrillation cycle length variability.

Authors:  Bokyung Min; Jeffrey Kluger; James S Kalus; Danette Guertin; Brian F McBride; C Michael White
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-07       Impact factor: 1.468

2.  Tachyarrhythmia Cycle Length in Appropriate versus Inappropriate Defibrillator Shocks in Brugada Syndrome, Early Repolarization Syndrome, or Idiopathic Ventricular Fibrillation.

Authors:  Woo Seok Lee; Jun Kim; Chang-Hee Kwon; Jin Hee Choi; Uk Jo; Yoo Ri Kim; Gi-Byoung Nam; Kee-Joon Choi; You-Ho Kim
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.